Table 2. Treatment outcomes with locoregional treatment by co-mutation status.
| Treatment | All patients (n=17) | KRAS-mutated | KRAS-wt | ||||
|---|---|---|---|---|---|---|---|
| All (n=10) | KEAP1-mut (n=2) | KEAP1-wt (n=8) | KEAP1-mut (n=3) | KEAP1-wt (n=4) | |||
| Surgery, n | 10 | 5 | 2 | 3 | 2 | 3 | |
| (Neo)adjuvant chemo, n [%] | 2 [20] | 1 [20] | 1 [50] | 0 | 1 [33] | 0 | |
| RFS post-surgery, years | |||||||
| Median (SD) | 34.8 (14.1) | 98.4 (18.4) | ** | 34.8 (26.4) | ** | 20.3 (9.0) | |
| 12-month PFS, n [%] | 9 [90] | 5 [100] | 2 [100] | 3 [100] | 2 [100] | 2 [67] | |
| 24-month PFS, n [%] | 7 [70] | 5 [100] | 2 [100] | 3 [100] | 2 [100] | 0 | |
| Concurrent with radiation, n | 8 | 5 | 0 | 5 | 1 | 2 | |
| RFS post-chemoradiation, months | |||||||
| Median (SD) | 7.1 (0.9) | 7.5 (1.4) | ** | 7.5 (1.4) | ** | ** | |
| 6-month PFS, n [%] | 6 [75] | 4 [80] | ** | 4 [80] | 1 [100] | 1 [50] | |
| 12-month PFS, n [%] | 3 [37] | 2 [40] | ** | 2 [40] | 1 [100] | 0 | |
| OS, all patients, years | |||||||
| Median (SD) | 8.6 (2.1) | 8.6 (2.4) | ** | 8.6 (2.5) | ** | 1.5 (0.5) | |
| % with recurrence, n [%] | 12 [71] | 6 [60] | 0 | 6 [75] | 2 [67] | 4 [100] | |
**, unable to calculate due to small number. SD, standard deviation; RFS, recurrence-free survival; PFS, progression-free survival; OS, overall survival.